TBvac-1, TBvac-2, TBvac-10
Candidate Overview
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Sponsor / Lead Developer: University of Minnesota
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Immunotherapy/Improving TB Cure Rates, Immunotherapy/Shortening TB treatment, Prevention of TB disease, and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, Elderly, Infants, People with active TB, People with MDR-TB, People with Mtb infection, and People without Mtb infection
Target Route of Administration: Intramuscular and Intranasal
Immune tissue localization: Lung
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: No
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | B-cell/Antibody | T-cell |
| T-cell phenotype | CD4 CD8 |
|
| T-cell functional profile | IFN-γ TNF-α |
|
| Preferential immune tissue localization | Spleen | Lung |
| Trained immunity | No | |